Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients

Basic and Clinical Pharmacology and Toxicology

Volumn 99, Issue 2, 2006, Pages 133-140

  Joerger, Markus ^a,c   Huitema, A D R ^a   Boogerd, W ^a   Van Der Sande, J J ^a   Schellens, J H M ^a,b   Beijnen, J H ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANASTROZOLE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBAMAZEPINE; CISPLATIN; DEXAMETHASONE; PHENYTOIN; TAMOXIFEN; VALPROIC ACID;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG MONITORING; DRUG PROTEIN BINDING; FEMALE; FLUORESCENCE POLARIZATION; GASTROINTESTINAL TOXICITY; HUMAN; HYPOALBUMINEMIA; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG ABUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; CARBAMAZEPINE; CREATININE; DEXAMETHASONE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; PHENYTOIN; RETROSPECTIVE STUDIES; SERUM ALBUMIN; TISSUE DISTRIBUTION; VALPROIC ACID;

EID: 33747061542     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_309.x     Document Type: Article

References (34)

1. Baird-Lambert, J.,M. P. Manglick, M.Wall & N. Buchanan: Identifying patients who might benefit from free phenytoin monitoring. Ther. Drug Monit. 1987, 9, 134-138.
2. Banh, H. L., M. E. Burton & M. R. Sperling: Interpatient and intrapatient variability in phenytoin protein binding. Ther. Drug Monit. 2002, 24, 379-385.
3. Benet, L. Z. & B. A. Hoener: Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Therap. 2002, 71, 115-121.
4. Burt, M., D. C. Anderson, J. Kloss & F. S. Apple: Evidence-based implementation of free phenytoin therapeutic drug monitoring. Clin. Chem. 2000, 46, 1132-1135.
5. Gattis,W. A. & D. B.May: Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Ann. Pharmacother. 1996, 30, 520-526.
6. Gilbert, M. R. & T. S. Armstrong: Management of seizures in the adult patient with cancer. Cancer Pract. 1995, 3, 143-149.
7. Gugler, R., D. W. Shoeman, D. H. Huffman, J. B. Cohlmia & D. L. Azarnoff: Pharmacokinetics of drugs in patients with the nephrotic syndrome. J. Clin. Invest. 1975, 55, 1182-1189.
8. Haidukewych, D., E. A. Rodin & J. J. Zielinski: Derivation and evaluation of an equation for prediction of free phenytoin concentration in patients co-medicated with valproic acid. Ther. Drug Monit. 1989, 11, 134-139.
9. Hayes, G. & M. E. Kootsikas: Reassessing the lower end of the phenytoin therapeutic range: a review of the literature. Ann. Pharmacotherap. 1993, 27, 1389-1392.
10. Hooper, W. D., F. Bochner, M. J. Eadie & J. H. Tyrer: Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin. Pharmacol. Therap. 1974, 15, 276-282.
11. Hung, C. C., C. J. Lin, C. C. Chen, C. J. Chang & H. H. Liou: Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther. Drug Monit. 2004, 26, 534-340.
12. Kilpatrick, C. J., S. Wanwimolruk & L. M. Wing: Plasma concentrations of unbound phenytoin in the management of epilepsy. Brit. J. Clin. Pharmacol. 1984, 17, 539-546.
13. Kowalski, K. G. & M. M. Hutmacher: Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test. J. Pharmacokinet. Pharmacodyn. 2001, 28, 253-275.
14. Koyama, H., N. Sugioka, A. Uno, S. Mori & K. Nakajima: Agerelated alteration of carbamazepine-serum protein binding in man. J. Pharm. Pharmacol. 1999, 51, 1009-1014.
15. Lackner, T. E.: Interaction of dexamethasone with phenytoin. Pharmacotherapy 1991, 11, 344-347.
16. Lai, M. L. & J. D. Huang: Dual effect of valproic acid on the pharmacokinetics of phenytoin. Biopharm. Drug Dispos. 1993, 14, 365-370.
17. Lawson, L. A., R. A. Blouin, R. B. Smith, R. P. Rapp & A. B. Young: Phenytoin-dexamethasone interaction: a previously unreported observation. Surg. Neurol. 1981, 16, 23-24.
18. Levy, R. H. & D. Schmidt: Utility of free level monitoring of antiepileptic drugs. Epilepsia 1985, 26, 199-205.
19. Mamiya, K., E. Yukawa, T. Matsumoto, C. Aita & S. Goto: Synergistic effect of valproate coadministration and hypoalbuminemia on the serum-free phenytoin concentration in patients with severe motor and intellectual disabilities. Clin. Neuropharmacol. 2002, 25, 230-233.
20. Neef, C. & I. de Voogd-van der Straaten: An interaction between cytostatic and anticonvulsant drugs. Clin. Pharmacol. Therap. 1988, 43, 372-375.
21. Peterson, G. M., S. McLean, S. Aldous, R. J. Von Witt & K. S. Millingen: Plasma protein binding of phenytoin in 100 epileptic patients. Brit. J. Clin. Pharmacol. 1982, 14, 298-300.
22. Peterson, G. M., B. H. Khoo & R. J. Von Witt: Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther. Drug Monit. 1991, 13, 415-419.
23. Porter, R. J. & R. B. Layzer: Plasma albumin concentration and diphenylhydantoin binding in man. Arch. Neurol. 1975, 32, 298-303.
24. Pospisil, J. & F. Perlik: Binding parameters of phenytoin during monotherapy and polytherapy. Int. J. Clin. Pharmacol. Ther. Toxicol. 1992, 30, 24-28.
25. Rabinowicz, A. L., D. R. Hinton, P. Dyck & W. T. Couldwell: High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia 1995, 36, 513-515.
26. Ratnaraj, N. & M. Hjelm: Prediction of free levels of phenytoin and carbamazepine in patients comedicated with valproic acid. Ther. Drug Monit. 1995, 17, 327-332.
27. Recuenco, I., E. Espinosa, B. Garcia & A. Carcas: Effect of dexamethasone on the decrease of serum phenytoin concentrations. Ann. Pharmacother. 1995, 29, 935.
28. Rimmer, E. M., D. C. Buss, P. A. Routledge & A. Richens: Should we routinely measure free plasma phenytoin concentration? Brit. J. Clin. Pharmacol. 1984, 17, 99-102.
29. Rowland, M. & T. N. Tozer: Dose and time dependencies. In: Clinical pharmacokinetics - Concepts and applications. Eds.: M. Rowland & T. N. Tozer. Williams & Wilkins, Philadelphia, U.S. 1995, pp. 407-411.
30. Ruegg, S.: Dexamethasone/phenytoin interactions: neurooncological concerns. Swiss Med. Wkly. 2002, 132, 425-426.
31. Tiula, E., L. G. Tallgren & P. J. Neuvonen: Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases. Int. J. Clin. Pharmacol. Ther. Toxicol. 1987, 25, 545-552.
32. Umstead, G. S. & K. H. Neumann: Correlation of free phenytoin to serum albumin in cancer patients. DICP 1990, 24, 923-926.
33. Wong, D. D., R. G. Longenecker, M. Liepman, S. Baker & M. LaVergne: Phenytoin-dexamethasone: a possible drug-drug interaction. J. Amer. Med. Ass. 1985, 254, 2062-2063.
34. Zielinski, J. J., D. Haidukewych & B. J. Leheta: Carbamazepinephenytoin interaction: elevation of plasma phenytoin concentrations due to carbamazepine comedication. Ther. Drug Monit. 1985, 7, 51-53.